AIM: To investigate the prevalence and clinical characteristics of vitiligo after allogeneic hematopoietic cell transplantation (AHCT). METHODS: The development of vitiligo was analyzed among 421 patients who underwent AHCT in Ibni Sina Hospital (University of Ankara) between 1988 and 2004. RESULTS: Among 421 patients, we describe 6 with generalized vitiligo occurring after AHCT for chronic myelogenous leukemia. Five of them had severe chronic graft-versus-host disease (GVHD). Vitiligo was accompanied by alopecia areata and acquired ichthyosis in 2 patients with GVHD. CONCLUSION: Melanocyte destruction caused by the autoimmune reactions triggered by chronic GVHD as well as a genetic predisposition might have played a role in the development of vitiligo in our patients. These data support the hypothesis that vitiligo is an autoimmune entity. Copyright 2008 S. Karger AG, Basel.
AIM: To investigate the prevalence and clinical characteristics of vitiligo after allogeneic hematopoietic cell transplantation (AHCT). METHODS: The development of vitiligo was analyzed among 421 patients who underwent AHCT in Ibni Sina Hospital (University of Ankara) between 1988 and 2004. RESULTS: Among 421 patients, we describe 6 with generalized vitiligo occurring after AHCT for chronic myelogenous leukemia. Five of them had severe chronic graft-versus-host disease (GVHD). Vitiligo was accompanied by alopecia areata and acquired ichthyosis in 2 patients with GVHD. CONCLUSION: Melanocyte destruction caused by the autoimmune reactions triggered by chronic GVHD as well as a genetic predisposition might have played a role in the development of vitiligo in our patients. These data support the hypothesis that vitiligo is an autoimmune entity. Copyright 2008 S. Karger AG, Basel.
Authors: Rena C Zuo; Haley B Naik; Seth M Steinberg; Kristin Baird; Sandra A Mitchell; Zoya Kuzmina; Steven Z Pavletic; Edward W Cowen Journal: JAMA Dermatol Date: 2015-01 Impact factor: 10.282
Authors: K J McElwee; A Gilhar; D J Tobin; Y Ramot; J P Sundberg; M Nakamura; M Bertolini; S Inui; Y Tokura; L E King; B Duque-Estrada; A Tosti; A Keren; S Itami; Y Shoenfeld; A Zlotogorski; R Paus Journal: Exp Dermatol Date: 2013-09 Impact factor: 3.960